{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE.","groups":[{"description":"Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.","id":"OG000","title":"Placebo"},{"description":"Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.","id":"OG001","title":"Palifermin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Twice-weekly from start of treatment up to 15 weeks after the start of treatment.","title":"Number of Patients With Grade 3 or 4 Mucositis as Measured by the World Heath Organization (WHO) Scale","type":"SECONDARY","unitOfMeasure":"Participants"}